Morepen Laboratories is currently trading at RS. 50.97, up by 1.87 points or 3.81% from its previous closing of RS. 49.10 on the BSE.

The stock opened at RS. 49.62 and touched a high of RS. 51.93 and a low of RS. 49.62 during the session. A total of 476914 shares have been traded so far.

The BSE group 'A' stock with a face value of RS. 2 recorded a 52-week high of RS. 100.80 on September 10, 2024, and a 52-week low of RS. 41.66 on April 7, 2025. Over the past week, the scrip’s high and low stood at RS. 51.93 and RS. 48.37 respectively. The current market capitalization of the company is RS. 2802.78 crore.

Promoters hold 35.65% stake in the company, while institutions hold 3.24% and non-institutions own 61.11%.

In a strategic development, Morepen Laboratories’ subsidiary, Morepen Medipath, has signed a Joint Venture (JV) agreement with Bimedical FZE to establish a JV company focused on manufacturing, trading, and selling medical device-related products. Morepen Medipath will acquire 50% stake in the JV, while Morepen Laboratories will indirectly hold 30% through its subsidiary.

Morepen Laboratories is engaged in the production and sale of APIs/Bulk Drugs, Home Diagnostics, Formulations, and OTC products.